[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100175804":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":26,"centralContacts":11,"locations":30,"responsibleParty":107,"collaborators":11,"id":109,"slug":110,"hasResults":111,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":11,"eligibilityCriteria":115,"healthyVolunteers":111,"sex":116,"minAge":117,"maxAge":118,"enrollmentInfo":119,"targetDuration":11,"studyType":122,"phases":123,"briefSummary":125,"conditions":126,"keywords":11,"overallStatus":130,"whyStopped":11,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":140},{"fullName":5,"class":6},"Novo Nordisk A\u002FS","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Adults","EXPERIMENTAL",null,[13],"Drug: activated recombinant human factor VII",{"label":15,"type":10,"description":11,"interventionNames":16},"Paediatric",[13],[18,23],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":11},"DRUG","activated recombinant human factor VII","A single bolus dose is administered. Injected intravenously",[9],{"type":19,"name":20,"description":24,"armGroupLabels":25,"otherNames":11},"A random order of a low\u002Fhigh dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously",[15],[27],{"name":28,"affiliation":5,"role":29},"Global Clinical Registry (GCR, 1452)","STUDY_DIRECTOR",[31,43,51,61,71,79,89,99],{"facility":32,"status":11,"city":33,"state":11,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":11},"Novo Nordisk Investigational Site","Bremen","28205","Germany","DE",{"type":38,"coordinates":39},"Point",[40,41],8.80717,53.07582,{"lat":41,"lon":40},{"facility":32,"status":11,"city":44,"state":11,"zip":45,"country":35,"countryCode":36,"cosmosGeoPoint":46,"geoPoint":50,"contacts":11},"Frankfurt","60590",{"type":38,"coordinates":47},[48,49],10.53333,49.68333,{"lat":49,"lon":48},{"facility":32,"status":11,"city":52,"state":11,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":60,"contacts":11},"Athens","GR-11527","Greece","GR",{"type":38,"coordinates":57},[58,59],23.72784,37.98376,{"lat":59,"lon":58},{"facility":32,"status":11,"city":62,"state":11,"zip":63,"country":64,"countryCode":65,"cosmosGeoPoint":66,"geoPoint":70,"contacts":11},"Florence","50134","Italy","IT",{"type":38,"coordinates":67},[68,69],11.24626,43.77925,{"lat":69,"lon":68},{"facility":32,"status":11,"city":72,"state":11,"zip":73,"country":64,"countryCode":65,"cosmosGeoPoint":74,"geoPoint":78,"contacts":11},"Milan","20124",{"type":38,"coordinates":75},[76,77],12.59836,42.78235,{"lat":77,"lon":76},{"facility":32,"status":11,"city":80,"state":11,"zip":81,"country":82,"countryCode":83,"cosmosGeoPoint":84,"geoPoint":88,"contacts":11},"Madrid","28046","Spain","ES",{"type":38,"coordinates":85},[86,87],-3.70256,40.4165,{"lat":87,"lon":86},{"facility":32,"status":11,"city":90,"state":11,"zip":91,"country":92,"countryCode":93,"cosmosGeoPoint":94,"geoPoint":98,"contacts":11},"London","WC1N 3JH","United Kingdom","UK",{"type":38,"coordinates":95},[96,97],-0.12574,51.50853,{"lat":97,"lon":96},{"facility":32,"status":11,"city":100,"state":11,"zip":101,"country":92,"countryCode":93,"cosmosGeoPoint":102,"geoPoint":106,"contacts":11},"Oxford","OX3 7LJ",{"type":38,"coordinates":103},[104,105],-1.25596,51.75222,{"lat":105,"lon":104},{"type":108,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100175804","phase-1-pharmacokinetics-of-single-bolus-dose-of-novoseven-in-paediatric-and-adult-patients-with-haemophilia-a-or-b-in-a-non--bleeding-state-100175804",false,"NCT01562587","Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State","Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non-Bleeding State","Inclusion Criteria:\n\n* Age 18-55 years and congenital haemophilia A or B male with severe FVIII or FX deficiency +\u002F-inhibitors\n* Age between 3-12 years and congenital haemophilia A or B male with record of inhibitors\n\nExclusion Criteria:\n\n* Known hypersensitivity to activated recombinant human factor VII or any of its components\n* Known clinical relevant coagulation diseases or insufficiencies other than congenital haemophilia\n* Clinical manifestation of HIV (human immunodeficiency virus) and\u002For protease inhibitor treatment\n* Clinical manifestation of active\u002Frecent bleeding\n* Administration of coagulation factor preparations within 24 hours of NovoSeven trial product dose administration\n* Body Mass Index (BMI) outside normal range\n* Known abuse of elicit drugs and\u002For alcohol\n* Renal insufficiency\n* Hepatic disease\n* Cardiovascular disease\n* Any disease or condition which, judged by the Investigator, could imply a potential hazard to the patient, interfere with the trial participation or trial outcome","MALE","3 Years","55 Years",{"count":120,"type":121},18,"ACTUAL","INTERVENTIONAL",[124],"PHASE1","This trial is conducted in Europe. The aim of this trial is to determine the pharmacokinetics of activated recombinant human factor VII (NovoSeven®) in haemophiliac patients in a non-bleeding state.",[127,128,129],"Congenital Bleeding Disorder","Haemophilia A","Haemophilia B","COMPLETED","2017-01-11",{"date":133,"type":134},"2017-01-12","ESTIMATED",{"date":136,"type":11},"2002-09",{"date":138,"type":121},"2003-05",{"name":5,"class":6},8]